|1.||Geller, David E: 10 articles (07/2015 - 07/2002)|
|2.||Konstan, Michael W: 10 articles (07/2014 - 03/2003)|
|3.||Burns, Jane L: 9 articles (04/2013 - 01/2002)|
|4.||Elborn, J Stuart: 8 articles (01/2015 - 05/2010)|
|5.||Ratjen, Felix: 6 articles (03/2014 - 06/2007)|
|6.||Angyalosi, Gerhild: 6 articles (03/2014 - 12/2009)|
|7.||Zhang, Jie: 6 articles (10/2013 - 01/2010)|
|8.||Høiby, Niels: 6 articles (05/2012 - 12/2005)|
|9.||O'Toole, George A: 5 articles (01/2015 - 04/2008)|
|10.||Nasr, Samya Z: 5 articles (03/2014 - 04/2002)|
01/01/2015 - "In the last decade, tobramycin inhalation has become an important contributor to CF treatment as a means to control chronic infection and as a first-line treatment for the eradication of early acquisition of P. "
07/01/2007 - "As opposed to normal saline irrigations, topical tobramycin led to a significant improvement in the degree of infection within an animal model of P. "
04/01/2007 - "We evaluated the pharmacokinetics (PK) and safety of tobramycin inhalation powder (TIP), a novel dry-powder formulation designed to deliver a high payload of tobramycin topically to the lungs for management of chronic Pseudomonas aeruginosa infections. "
09/01/1981 - "The infection was cured more frequently in patients who achieved a high ratio between the peak serum concentration of tobramycin and the minimal inhibitory concentration of tobramycin against the pathogenic organism (so-called therapeutic ratio). "
01/01/2014 - "Results after two years suggested treatment of early infection results in microbiological eradication of Pseudomonas aeruginosa more often than no anti-pseudomonal treatment, odds ratio 0.12 (95% confidence interval 0.02 to 0.79).One trial comparing 28 days to 56 days treatment with nebulised tobramycin solution for inhalation in 88 participants showed that both treatments were effective and well-tolerated, with no notable additional improvement with longer over shorter duration of therapy. "
|2.||Cystic Fibrosis (Mucoviscidosis)
01/01/2007 - "Delivery of tobramycin by inhalation to the lungs of patients with cystic fibrosis (CF) who are infected with Pseudomonas aeruginosa has been proven to be effective and safe. "
01/01/2000 - "Phase III trials of the aerosolized delivery of tobramycin to cystic fibrosis (CF) patients demonstrated a significant improvement in pulmonary function and in sputum bacterial density. "
01/01/2015 - "In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients."
03/15/2003 - "We conclude that 28 days of tobramycin solution for inhalation of 300 mg twice daily is safe and effective for significant reduction of lower airway Pa density in young children with cystic fibrosis."
06/01/2014 - "Clinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV1 in cystic fibrosis."
01/01/1978 - "We evaluated several therapeutic modifications in an attempt to improve efficacy of topical therapy with tobramycin of experimental Pseudomonas keratitis in guinea pigs. "
05/01/1987 - "Finally, a Pseudomonas aeruginosa keratitis model in the rat demonstrates the antibiotic efficacy of topical tobramycin treatment over untreated controls (P less than 0.00001), and a progressively enhanced efficacy with increasing tobramycin concentrations is suggested. "
05/01/1979 - "We determined the efficacy of tobramycin administered by topical, intramuscular, and subconjunctival routes in guinea pigs and rabbits with experimental Pseudomonas keratitis. "
03/01/2015 - "Despite bacterial colonization in 9 CLs, no clinical signs of infectious keratitis were found in any of the patients with prophylactic topical tobramycin 3%. "
07/01/2001 - "The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis."
07/01/1986 - "Tobramycin therapy for lethal sepsis in the dog."
09/01/1984 - "Five clinical strategies for monitoring serum tobramycin concentrations were compared in a population of children and young adults with normal renal function receiving tobramycin for suspected sepsis. "
01/01/1994 - "Its antimicrobial spectrum and bactericidal activity make tobramycin an appropriate agent for treatment of sepsis caused by gram-negative bacteria and its lack of propensity to elicit excessive release of endotoxin may avoid exacerbation of endotoxin-related shock in sepsis."
01/01/1992 - "Six of eight rabbits receiving IM tobramycin had wound infections, and five of five in whom non-antibiotic-containing beads had been implanted had significant wound infections, with one of the five dying of sepsis on the 3rd day of the experiment. "
09/01/1986 - "[Dynamics of the contamination of mice during the treatment of burn sepsis due to Pseudomonas aeruginosa using tobramycin alone or combined with active and passive immunization]."
01/22/2000 - "The aim of this study was to assess renal and respiratory tolerance of aerosolized tobramycin in intubated and mechanically ventilated patients with nosocomial pneumonia. "
03/01/1999 - "To study the penetration of tobramycin in lung tissue evaluated as the concentration in epithelial lining fluid and to characterize the time course of the drug in the treatment of patients with pneumonia. "
11/01/2011 - "In the current investigation, our laboratory tested the hypothesis that aerosolized rhLZ can potentiate the effects of tobramycin (TBMN), thereby reducing the effective dose of this agent in the treatment of PA-induced pneumonia. "
01/01/2011 - "Adding the results from the three patients together, the number of pneumonias went from 19 during the year prior to starting the nebulized tobramycin, to 11 during the year of treatment. "
10/01/2009 - "In the rat pneumonia model, FTI and tobramycin demonstrated bactericidal killing of P. "
|6.||Anti-Bacterial Agents (Antibiotics)
|2.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|4.||Artificial Respiration (Mechanical Ventilation)
|5.||Intensive Care (Surgical Intensive Care)